Targeted activation of GPER enhances the efficacy of venetoclax by boosting leukemic pyroptosis and CD8+ T cell immune function in acute myeloid leukemia

Acute myeloid leukemia (AML) is a rapidly progressing and often fatal hematopoietic malignancy. Venetoclax (VEN), a recent FDA-approved BCL-2 selective inhibitor, has high initial response rates in elderly AML patients, but the majority of patients eventually acquire resistance. Multiple studies hav...

Descripción completa

Detalles Bibliográficos
Autores principales: Ren, Jun, Tao, Yonghong, Peng, Meixi, Xiao, Qiaoling, Jing, Yipei, Huang, Junpeng, Yang, Jing, Lin, Can, Sun, Minghui, Lei, Li, Yang, Zesong, Yang, Zailin, Zhang, Ling
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9622865/
https://www.ncbi.nlm.nih.gov/pubmed/36316313
http://dx.doi.org/10.1038/s41419-022-05357-9

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9622865/
https://www.ncbi.nlm.nih.gov/pubmed/36316313
http://dx.doi.org/10.1038/s41419-022-05357-9

Ejemplares similares